Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: A retrospective medical claims analysis

Journal of Sexual Medicine

Volumn 10, Issue 5, 2013, Pages 1401-1409

  Schoenfeld, Michael Jay ^a   Shortridge, Emily ^a   Cui, Zhanglin ^a   Muram, David ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Hypogonadism; Testosterone Replacement Therapy; Transdermal Testosterone Therapy; Treatment Pattern

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; DRUG DOSE ESCALATION; DRUG MEGADOSE; GENERAL PRACTITIONER; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; TOPICAL TREATMENT; TREATMENT DURATION;

EID: 84876969942     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12114     Document Type: Article

References (38)

1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497.
2. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation 2009;119:3028-3035.
3. Dunbar-Jacob J, Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Dowswell WM. Adherence in chronic disease. Annu Rev Nurs Res 2000;18:48-90.
4. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050-2058.
5. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB. Low free testosterone predicts mortality from cardiovascular disease but not other causes: The Health in Men Study. J Clin Endocrinol Metab 2012;97:179-189.
6. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
7. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-685.
8. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-4510.
9. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964-969.
10. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69-74.
11. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-2681.
12. Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population-a patient-based register study. BMC Health Serv Res 2011;11:326.
13. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-740.
14. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-47.
15. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-3796.
16. Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277-283.
17. ®, Giltay EJ, Gooren LJ. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012;15:198-207.
18. Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM. Testosterone replacement therapy among elderly males: The Testim Registry in the US (TRiUS). Clin Interv Aging 2012;7:321-330.
19. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011;82:328-334.
20. Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila) 2011;4:1360-1365.
21. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-443.
22. Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J. Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006;29:1997-2002.
23. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: Retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005;27:1639-1646.
24. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-1073.
25. Lacasse Y, Archibald H, Ernst P, Boulet LP. Patterns and determinants of compliance with inhaled steroids in adults with asthma. Can Respir J 2005;12:211-217.
26. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164:2343-2348.
27. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: A key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-362.
28. Senior V, Marteau TM, Weinman J, Genetic Risk Assessment for FH Trial (GRAFT) Study Group. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: The role of illness perceptions. Cardiovasc Drugs Ther 2004;18:475-481.
29. Kim YS, Sunwoo S, Lee HR, Lee KM, Park YW, Shin HC, Kim CH, Kim DH, Kim BS, Cha HS, Huh BY, Korea Post-Marketing Surveillance Research Group. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002;11:593-600.
30. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: A 3 year longitudinal study. J Rheumatol 1999;26:2114-2122.
31. National Institute on Aging. Sexuality in Later Life. 2009. Available at: http://www.nia.nih.gov/health/publication/sexuality-later-life. Last Updated 2012 (accessed September 25, 2012).
32. Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R. The direct and indirect costs among U.S. privately insured employees with hypogonadism. J Sex Med 2012;9:2438-2447.
33. Clatworthy J, Bowskill R, Rank T, Parham R, Horne R. Adherence to medication in bipolar disorder: A qualitative study exploring the role of patients' beliefs about the condition and its treatment. Bipolar Disord 2007;9:656-664.
34. Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. J Psychosom Res 2005;58:403-415.
35. ® 1% (testosterone gel). Prescribing information. September 2009. Available at: http://www.testim.com/pdf/Testim_PI_Medication_Guide.pdf (accessed September 8, 2012).
36. ® (testosterone gel) 1%. Prescribing information. September 2012. Available at: http://www.rxabbvie.com/pdf/androgel_PI.pdf (accessed September 8, 2012).
37. Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: Results of a 182-day open-label extension of a 6-month double-blind study. J Sex Med 2012;9:1149-1161.
38. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-286.